Treace Medical Concepts — Third Quarter 2026 Earnings Summary

Treace Medical Concepts reported third-quarter 2026 revenue of $48.3 million, a 4% decrease from the prior year, driven by a shift toward lower-priced minimally invasive products. The company reduced its net loss to $12.6 million, representing a 23% improvement year-over-year, while Adjusted EBITDA turned positive at $0.3 million. Cash usage for the first nine months of 2026 decreased by 53% compared to the same period in 2025, leaving the company with $39.8 million in cash and marketable securities. Treace updated its full-year 2026 revenue guidance to a range of $206 million to $210 million and expects an Adjusted EBITDA loss between $1.0 million and $2.0 million.